Clinical Trial Update: New Therapeutic Target for Toxic Epidermal Necrolysis (TEN) Using Anti-CD38+ Monoclonal Antibodies. [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial is investigating anti-CD38+ monoclonal antibodies as a new therapeutic target for Toxic Epidermal Necrolysis, with the study not yet recruitin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Toxic Epidermal Necrolysis

Drugs mentioned

• Anti-CD38 monoclonal antibody therapy

Snippet

Sponsor: Hospices Civils de Lyon | Conditions: Toxic Epidermal Necrolysis, Immunotherapy | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING